IMRX Financials

Income Statement
MetricQ3 2026Q2 2026Q1 2026Q4 2025Q3 2025
Revenue
0
0
0
0
0
Cost of Revenue
0
0
0
0
0
Gross Profit
0
0
0
0
0
Operating Expenses
25.8M
+35.7%
19.0M
+23.9%
15.3M
+11.5%
13.8M
-10.6%
15.4M
R&D
20.7M
+48.0%
14.0M
+31.5%
10.6M
+15.0%
9.3M
-14.8%
10.9M
SG&A
5.1M
+1.3%
5.0M
+6.7%
4.7M
+4.3%
4.5M
-0.3%
4.5M
Operating Income
-25788019
-35.7%
-19000408
-23.9%
-15335034
-11.5%
-13752719
+10.6%
-15380706
EBITDA
-25694575
-35.9%
-18908638
-24.0%
-15246315
-11.5%
-13669513
+10.6%
-15294549
Net Income
-24192583
-40.1%
-17270427
-28.3%
-13460895
-16.2%
-11580010
+22.6%
-14964875
EPS (Basic)
$-0.37
-37.0%
$-0.27
-28.6%
$-0.21
-16.7%
$-0.18
+52.6%
$-0.38
EPS (Diluted)
$-0.37
-37.0%
$-0.27
-28.6%
$-0.21
-16.7%
$-0.18
+52.6%
$-0.38
Shares (Diluted)
64.7M
+0.0%
64.7M
+0.1%
64.7M
-0.3%
64.9M
+63.5%
39.7M
Immuneering (IMRX) — Financials